Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
House dust mite allergen extract (Roxall Medizin) is a biological product developed for sublingual immunotherapy (SLIT) to treat perennial allergic rhinitis caused by house dust mites (*Dermatophagoides pteronyssinus* and *Dermatophagoides farinae*). The extract is administered sublingually to induce desensitization and immunological tolerance. It works by shifting the immune response from a pro-allergic Th2 profile toward a Th1 and regulatory T-cell (Treg) response, leading to the production of allergen-specific IgG4 antibodies and a reduction in IgE-mediated allergic inflammation. This desensitization process aims to provide long-term relief from symptoms such as sneezing, rhinorrhea, and nasal congestion, while reducing the patient's reliance on symptomatic medications.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on House dust mite allergen extract (Roxall Medizin).